Literature DB >> 8204318

Detection of Chlamydia trachomatis in general practice urine samples.

M S Dryden1, M Wilkinson, M Redman, M R Millar.   

Abstract

BACKGROUND: Chlamydia trachomatis is frequently overlooked as a cause of dysuria and urinary frequency in general practice patients. AIM: This study set out to determine the impact of performing chlamydial antigen detection on sterile pyuria samples from patients aged 16-65 years and which were submitted to a hospital microbiology laboratory by general practitioners in the Winchester health district for routine microbiological investigations.
METHOD: Chlamydial antigen detection was performed by enzyme immunoassay and direct immunofluorescence. The cost of performing the test was estimated. In the first year of the study (1991) questionnaires were sent to general practitioners whose patients had a positive test result.
RESULTS: A total of 1025 samples of sterile pyuria were received at the laboratory between January 1991 and March 1993. Chlamydial antigen was detected in 54 samples (5%); 22 men and 32 women aged between 16 and 57 years (mean 25 years). The detection rate was highest in the 16-20 years age group (22% of men had a positive sample and 7% of women). Completed questionnaires from 27 general practitioners revealed that 59% of their patients were referred to the genitourinary clinic for treatment and contact tracing. The others were treated by the general practitioner. The cost of the screening programme per cure in this population was estimated to be 246 pounds.
CONCLUSION: C trachomatis is a significant pathogen which may go unrecognized and untreated. The cost, medically and financially, of screening for this pathogen and treating infected patients and contacts is likely to be less than ignoring it, particularly if screening is confined to the 16-30 years age group. General practitioners should consider the diagnosis of chlamydial infection in young adult patients with sterile pyuria, and microbiology laboratories should screen sterile pyuria samples for chlamydial antigen.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8204318      PMCID: PMC1238812     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  12 in total

1.  Screening for Chlamydia trachomatis in adolescent males: a cost-based decision analysis.

Authors:  A G Randolph; A E Washington
Journal:  Am J Public Health       Date:  1990-05       Impact factor: 9.308

2.  Detection of Chlamydia trachomatis in urinary samples from women.

Authors:  L O Svensson; I Mares; S E Olsson
Journal:  Genitourin Med       Date:  1991-04

Review 3.  Laboratory techniques for the diagnosis of chlamydial infections.

Authors:  D Taylor-Robinson; B J Thomas
Journal:  Genitourin Med       Date:  1991-06

4.  Simple microbiological method for the identification of antimicrobial agents prescribed in general practice.

Authors:  M R Millar; P Langdale
Journal:  J Clin Microbiol       Date:  1985-05       Impact factor: 5.948

5.  Detection of Chlamydia trachomatis in first-void urine collected from men and women attending a venereal clinic.

Authors:  M Genç; A Stary; S Bergman; P A Mårdh
Journal:  APMIS       Date:  1991-05       Impact factor: 3.205

6.  False-positive Chlamydiazyme results during urine sediment analysis due to bacterial urinary tract infections.

Authors:  J Demaio; R S Boyd; R Rensi; A Clark
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

7.  Use of a urine enzyme immunoassay as a diagnostic tool for Chlamydia trachomatis urethritis in men.

Authors:  J R Schwebke; A M Clark; M B Pettinger; P Nsubga; W E Stamm
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

8.  Screening for Chlamydia trachomatis in military personnel by urine testing.

Authors:  A Stary; K Steyrer; C Heller-Vitouch; I Müller; P A Mårdh
Journal:  Infection       Date:  1991 Jul-Aug       Impact factor: 3.553

9.  First catch urine sediment for Chlamydia trachomatis and Neisseria gonorrhoeae culture in adolescent males with pyuria.

Authors:  E R Woods; L M Galvez; A L Talis; S J Emans
Journal:  J Adolesc Health       Date:  1991-06       Impact factor: 5.012

10.  Causes of the acute urethral syndrome in women.

Authors:  W E Stamm; K F Wagner; R Amsel; E R Alexander; M Turck; G W Counts; K K Holmes
Journal:  N Engl J Med       Date:  1980-08-21       Impact factor: 91.245

View more
  7 in total

Review 1.  One to one interventions to reduce sexually transmitted infections and under the age of 18 conceptions: a systematic review of the economic evaluations.

Authors:  L Barham; D Lewis; N Latimer
Journal:  Sex Transm Infect       Date:  2007-07-11       Impact factor: 3.519

2.  Behavioural and demographic characteristics of attenders at two genitourinary medicine clinics in England.

Authors:  M Catchpole; N Connor; A Brady; G Kinghorn; D Mercey; B Band; N Thin
Journal:  Genitourin Med       Date:  1997-12

Review 3.  The role of epidemiology and surveillance systems in the control of sexually transmitted diseases.

Authors:  M A Catchpole
Journal:  Genitourin Med       Date:  1996-10

Review 4.  Screening for Chlamydia trachomatis: a systematic review of the economic evaluations and modelling.

Authors:  T E Roberts; S Robinson; P Barton; S Bryan; N Low
Journal:  Sex Transm Infect       Date:  2006-06       Impact factor: 3.519

5.  Chlamydia trachomatis.

Authors:  C Thompson; E Wallace
Journal:  Br J Gen Pract       Date:  1994-12       Impact factor: 5.386

6.  Opportunistic screening for genital chlamydial infection. II: prevalence among healthcare attenders, outcome, and evaluation of positive cases.

Authors:  J M Pimenta; M Catchpole; P A Rogers; J Hopwood; S Randall; H Mallinson; E Perkins; N Jackson; C Carlisle; G Hewitt; G Underhill; T Gleave; L McLean; A Ghosh; J Tobin; V Harindra
Journal:  Sex Transm Infect       Date:  2003-02       Impact factor: 3.519

Review 7.  General practice update: chlamydia infection in women.

Authors:  P Oakeshott; P Hay
Journal:  Br J Gen Pract       Date:  1995-11       Impact factor: 5.386

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.